United States
|
|
| Product Center | |
 Bacteroides Bile Esculin Agar (BBE) |
|
| Cat. # | Desc. | Qty. | Unit |
| 221836 | Bacteroides Bile Esculin Agar (BBE) | 10 | SP |
Bacteroides Bile Esculin Agar (BBE) is recommended as a primary isolation medium for the selection and presumptive identification of the B. fragilis group.1,2
| Catalog # | Description | Quantity | Unit |
| 221836 | Bacteroides Bile Esculin Agar (BBE) | 10 | SP |
Bacteroides Bile Esculin Agar (BBE) is recommended as a primary isolation medium for the selection and presumptive identification of the B. fragilis group.1,2 Bacteroides Bile Esculin Agar (BBE) is recommended as a primary isolation medium for the selection and presumptive identification of the B. fragilis group.1,2 Among the most frequently encountered anaerobes in human clinical infections are members of the "Bacteroides fragilis group." Rapid detection and identification of these organisms is important since they have been found to be more resistant to antimicrobial therapy than other anaerobes.3 B. fragilis and B. thetaiotaomicron are the species of greatest clinical significance.3 Other species in the group include: B. caccae, B. distasonis, B. eggerthii, B. merdae, B. ovatus, B. stercoris, B. uniformis and B. vulgatus. Frequently these pathogens occur in a mixture of microorganisms which may overgrow the primary isolation medium. Selective media, such as CDC Anaerobe 5% Sheep Blood Agar with Kanamycin and Vancomycin, have been recommended as appropriate for primary isolation.4 However, limited evidence for the presumptive identification of the B. fragilis group was provided. In 1978, Livingston et al. described a primary plating medium (BBE) which was found to provide selective recovery of the B. fragilis group and also evidence for presumptive identification.1 Among the most frequently encountered anaerobes in human clinical infections are members of the "Bacteroides fragilis group." Rapid detection and identification of these organisms is important since they have been found to be more resistant to antimicrobial therapy than other anaerobes.3 B. fragilis and B. thetaiotaomicron are the species of greatest clinical significance.3 Other species in the group include: B. caccae, B. distasonis, B. eggerthii, B. merdae, B. ovatus, B. stercoris, B. uniformis and B. vulgatus. Frequently these pathogens occur in a mixture of microorganisms which may overgrow the primary isolation medium. Selective media, such as CDC Anaerobe 5% Sheep Blood Agar with Kanamycin and Vancomycin, have been recommended as appropriate for primary isolation.4 However, limited evidence for the presumptive identification of the B. fragilis group was provided. In 1978, Livingston et al. described a primary plating medium (BBE) which was found to provide selective recovery of the B. fragilis group and also evidence for presumptive identification.1 See "Quality Control Procedures." Quality control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory’s standard Quality Control procedures. It is recommended that the user refer to pertinent CLSI (formerly NCCLS) guidance and CLIA regulations for appropriate Quality Control practices.
For in vitro Diagnostic Use. If excessive moisture is observed, invert the bottom over an off-set lid and allow to air dry in order to prevent formation of a seal between the top and bottom of the plate during incubation. Pathogenic microorganisms, including hepatitis viruses and Human Immunodeficiency Virus, may be present in clinical specimens. "Standard Precautions"5-8 and institutional guidelines should be followed in handling all items contaminated with blood and other body fluids. After use, prepared plates, specimen containers and other contaminated materials must be sterilized by autoclaving before discarding. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Information shown on this page is a short summary extracted from the QC/PI Manual, available as a PDF under the Related Documents section of this page.
